Geron Corp (GERN)
NASDAQ:GERN
Want to see GERN full AI Analyst Report?
GERN Stock Chart & Stats
$1.68
<$0.01(0.15%)
At close: 4:00 PM EST
$1.68
<$0.01(0.15%)
Day’s Range― - ―
52-Week Range$1.04 - $2.01
Previous CloseN/A
Volume1.63M
Average Volume (3M)19.38M
Market Cap
$891.71M
Enterprise Value$1.07B
Total Cash (Recent Filing)$314.29M
Total Debt (Recent Filing)$251.84M
Price to Earnings (P/E)―
Beta1.44
Next Earnings
Aug 06, 2026EPS Estimate
>-0.01Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-0.10
Shares Outstanding641,521,000
10 Day Avg. Volume20,541,080
30 Day Avg. Volume19,376,032
Financial Highlights & Ratios
PEG Ratio0.20
Price to Book (P/B)3.90
Price to Sales (P/S)4.79
P/FCF Ratio-7.92
Enterprise Value/Market Cap1.20
Enterprise Value/Revenue5.45
Enterprise Value/Gross Profit6.30
Enterprise Value/Ebitda-26.29
Forecast
1Y Price Target
$3.25Price Target Upside93.45% Upside
Rating ConsensusModerate Buy
Number of Analyst Covering5
EPS Forecast (FY)-0.04
Revenue Forecast (FY)$231.28M
Bulls Say, Bears Say
Bulls Say
Commercial Rollout And AdoptionThe commercial launch of Rytelo is showing increasing demand with a growing base of ordering accounts and rising use in earlier lines of therapy, indicating expanding market acceptance beyond initial patient groups.
Financial FlexibilitySubstantial cash reserves, access to additional debt financing, and disciplined spending provide financial flexibility to support the Rytelo launch and a path toward breakeven.
Revenue Guidance And Growth OutlookManagement reiterated revenue guidance and signaled that new marketing and commercial initiatives are expected to accelerate sales, supporting analyst confidence in the company's growth trajectory.
Bears Say
Commercial Penetration RiskCommercial strategy relies on expanding use in second-line patients but current patient penetration remains low and early provider interest has not consistently translated into revenue.
Net Revenue PressureRising gross-to-net adjustments, partly driven by contracts with group purchasing organizations in community settings, are reducing net revenue per unit and could constrain overall revenue growth.
Weak Near-term Sales PerformanceReported revenue fell short of analyst expectations and Rytelo sales were flat, undermining near-term revenue momentum and investor confidence.
Geron News
GERN FAQ
What was Geron Corp’s price range in the past 12 months?
Geron Corp lowest stock price was $1.04 and its highest was $2.01 in the past 12 months.
What is Geron Corp’s market cap?
Geron Corp’s market cap is $891.71M.
When is Geron Corp’s upcoming earnings report date?
Geron Corp’s upcoming earnings report date is Aug 06, 2026 which is in 87 days.
How were Geron Corp’s earnings last quarter?
Geron Corp released its earnings results on May 06, 2026. The company reported -$0.01 earnings per share for the quarter, beating the consensus estimate of -$0.02 by $0.01.
Is Geron Corp overvalued?
According to Wall Street analysts Geron Corp’s price is currently Undervalued.
Does Geron Corp pay dividends?
Geron Corp does not currently pay dividends.
What is Geron Corp’s EPS estimate?
Geron Corp’s EPS estimate is >-0.01.
How many shares outstanding does Geron Corp have?
Geron Corp has 641,521,000 shares outstanding.
What happened to Geron Corp’s price movement after its last earnings report?
Geron Corp reported an EPS of -$0.01 in its last earnings report, beating expectations of -$0.02. Following the earnings report the stock price went down -4.242%.
Which hedge fund is a major shareholder of Geron Corp?
Currently, no hedge funds are holding shares in GERN
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Geron Stock Smart Score
Neutral
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Moderate Buy
Average Price Target:
$3.25 (93.45% Upside)
$3.25 (93.45% Upside)
Blogger Sentiment
Bullish
GERN Sentiment 100%
Sector Average 72%
Sector Average 72%
Hedge Fund Trend
Increased
By 5.1M Shares
Last Quarter.
Last Quarter.
Crowd Wisdom
Neutral
Last 7 Days <0.1%
Last 30 Days ▲ 0.4%
Last 30 Days ▲ 0.4%
News Sentiment
Very Bullish
Bullish news 100%
Bearish news 0%
Bearish news 0%
Technicals
SMA
Positive
20 days / 200 days
Momentum
32.28%
12-Months-Change
Fundamentals
Return on Equity
-28.90%
Trailing 12-Months
Asset Growth
-5.04%
Trailing 12-Months
Company Description
Geron Corp
Geron Corporation, a late-stage clinical biopharmaceutical company, focuses on the development and commercialization of therapeutics for myeloid hematologic malignancies. It develops imetelstat, a telomerase inhibitor that is in Phase 3 clinical trials, which inhibits the uncontrolled proliferation of malignant stem and progenitor cells in hematologic myeloid malignancies for the treatment of low or intermediate-1 risk myelodysplastic syndromes and intermediate-2 or high-risk myelofibrosis. The company was incorporated in 1990 and is headquartered in Foster City, California.
GERN Earnings Call
Q1 2026
0:00 / 0:00
Earnings Call Sentiment|Positive
The call conveyed a largely positive operational and commercial story: strong revenue growth (+31% YoY), expanding demand (+6% QoQ) and disciplined cost reductions position Geron to meet 2026 guidance. Important clinical and regulatory milestones (IMpactMF enrollment, NCCN order template inclusion, peer-reviewed publication) bolster the long-term value proposition. Key risks highlighted include widening gross-to-net pressure (21% vs 13% prior year), a meaningful quarter-over-quarter cash decline (~$60M) driven by one-time and supply investments, and unresolved European commercialization/pricing decisions. On balance, the favorable revenue trajectory, cost discipline and clinical progress outweigh the manageable near-term financial and market-access headwinds.View all GERN earnings summariesGERN Stock 12 Month Forecast
Average Price Target
$3.25
▲(93.45% Upside)
Technical Analysis
Ownership Overview
0.06% Insiders
10.91% Mutual Funds
1.35% Other Institutional Investors
72.79% Public Companies and
Individual Investors